CN118946566A - 作为泛素特异性蛋白酶7抑制剂的杂环化合物 - Google Patents
作为泛素特异性蛋白酶7抑制剂的杂环化合物 Download PDFInfo
- Publication number
- CN118946566A CN118946566A CN202380027580.0A CN202380027580A CN118946566A CN 118946566 A CN118946566 A CN 118946566A CN 202380027580 A CN202380027580 A CN 202380027580A CN 118946566 A CN118946566 A CN 118946566A
- Authority
- CN
- China
- Prior art keywords
- methyl
- phenyl
- chloro
- pyrrolo
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2200753.8A GB202200753D0 (en) | 2022-01-21 | 2022-01-21 | Pharmaceutical compounds |
| GB2200753.8 | 2022-01-21 | ||
| PCT/EP2023/051447 WO2023139241A1 (en) | 2022-01-21 | 2023-01-20 | Heterocyclic compounds as ubiquitin specific protease 7 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118946566A true CN118946566A (zh) | 2024-11-12 |
Family
ID=80507367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380027580.0A Pending CN118946566A (zh) | 2022-01-21 | 2023-01-20 | 作为泛素特异性蛋白酶7抑制剂的杂环化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250122223A1 (https=) |
| EP (1) | EP4466072A1 (https=) |
| JP (1) | JP2025503052A (https=) |
| CN (1) | CN118946566A (https=) |
| GB (1) | GB202200753D0 (https=) |
| WO (1) | WO2023139241A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202001980D0 (en) * | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
| US20240150362A1 (en) | 2022-08-25 | 2024-05-09 | Molecure S.A. | Substituted Pyrrolotriazines |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2200753B (en) | 1986-12-23 | 1991-01-23 | Brookes & Gatehouse | Speed measurement device |
| EP1749822B1 (en) | 2005-08-05 | 2008-10-15 | Hybrigenics S.A. | Novel cysteine protease inhibitors and their therapeutic applications |
| US7875613B2 (en) | 2006-10-30 | 2011-01-25 | Hybrigenics Sa | Tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |
| EP2208725A1 (en) | 2009-01-13 | 2010-07-21 | Hybrigenics S.A. | Novel specific inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications |
| WO2010114881A1 (en) | 2009-04-01 | 2010-10-07 | Progenra Inc. | Anti-neoplastic compounds, compositions and methods |
| US20110177105A1 (en) | 2010-01-15 | 2011-07-21 | Roman Lopez | Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| AR103297A1 (es) | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| US9938300B2 (en) | 2015-02-05 | 2018-04-10 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| US9840491B2 (en) | 2015-02-05 | 2017-12-12 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
| EP3253765A1 (en) | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| CN107531683B (zh) | 2015-03-20 | 2022-05-13 | 豪夫迈·罗氏有限公司 | Usp7抑制剂化合物及使用方法 |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| GB202001980D0 (en) | 2020-02-13 | 2020-04-01 | Almac Discovery Ltd | Therapeutic mentods |
-
2022
- 2022-01-21 GB GBGB2200753.8A patent/GB202200753D0/en not_active Ceased
-
2023
- 2023-01-20 WO PCT/EP2023/051447 patent/WO2023139241A1/en not_active Ceased
- 2023-01-20 US US18/729,403 patent/US20250122223A1/en active Pending
- 2023-01-20 EP EP23701878.3A patent/EP4466072A1/en active Pending
- 2023-01-20 JP JP2024543181A patent/JP2025503052A/ja active Pending
- 2023-01-20 CN CN202380027580.0A patent/CN118946566A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250122223A1 (en) | 2025-04-17 |
| WO2023139241A1 (en) | 2023-07-27 |
| EP4466072A1 (en) | 2024-11-27 |
| GB202200753D0 (en) | 2022-03-09 |
| JP2025503052A (ja) | 2025-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6647371B2 (ja) | １，３−チアゾール−２−イル置換ベンズアミド | |
| CN105683188B (zh) | 作为fgfr4抑制剂的稠环二环吡啶基衍生物 | |
| TW202110837A (zh) | 氫化吡啶并嘧啶類衍生物、其製備方法及其在醫藥上的應用 | |
| CN110799509A (zh) | Pd-1/pd-l1抑制剂 | |
| CN111801320A (zh) | 苯甲酰胺化合物 | |
| CN112739420A (zh) | 苯氧基-吡啶基-嘧啶化合物及使用方法 | |
| US20240238424A1 (en) | Heterobifunctional compounds and methods of treating disease | |
| CN114014844A (zh) | 氨基吡啶衍生物及其作为选择性alk-2抑制剂的用途 | |
| TW202333663A (zh) | Rxfp1促效劑 | |
| CN118946566A (zh) | 作为泛素特异性蛋白酶7抑制剂的杂环化合物 | |
| WO2022096018A1 (zh) | 一类新型苯并二氮䓬类化合物、其制备方法及其用途 | |
| TWI860334B (zh) | 芳香族衍生物、包括其之藥物組合物與試劑盒及其用途 | |
| KR20230160901A (ko) | 유비퀴틴 특이 프로테아제 19(usp19)의 억제제로서의 약제학적 화합물 | |
| EP4587429B1 (en) | Substituted oxoisoindolinyl piperidine-2,6-dione compounds | |
| US12577227B2 (en) | WDR5 inhibitors and modulators | |
| EP3672962A1 (en) | Morpholinylpyridone compounds | |
| CN106573927B (zh) | 氧杂环庚烷-2-基-吡唑-4-基-杂环基-甲酰胺化合物和使用方法 | |
| CN109476638A (zh) | 吡唑衍生物、其组合物及治疗用途 | |
| RU2826177C1 (ru) | Производные аминопиридина и их применение в качестве селективных ингибиторов alk-2 | |
| HK40051446A (en) | Phenoxy-pyridyl-pyrimidine compounds and methods of use | |
| WO2023030215A1 (zh) | 吡啶并嘧啶酮类衍生物及其制备方法和用途 | |
| CN117425658A (zh) | 用作ras抑制剂的喹唑啉衍生物 | |
| HK40040054A (en) | Aromatic derivatives, preparation methods, and medical uses thereof | |
| HK40017188A (en) | Pd-1/pd-l1 inhibitors | |
| EA049492B1 (ru) | Производные аминопиридина и их применение в качестве селективных ингибиторов alk–2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |